Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?

Sebastian SchwindLara BischofMarius BillJuliane GrimmJule UssmannDonata BackhausDominic BrauerTung Pham ThanhMaximilian MerzGeorg-Nikolaus FrankeKlaus H MetzelerVladan VucinicMarco HerlingUwe PlatzbeckerMadlen Jentzsch

Published in: HemaSphere (2024)

Keyphrases

stem cell transplantation
high dose
acute myeloid leukemia
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
bone marrow
low dose
acute lymphoblastic leukemia